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Abstract 21 
Daily physical activity becomes reduced in precapillary pulmonary hypertension (PH) 22 
but the underlying mechanisms are inadequately explored. We sought to investigate 23 
clinical and physiological relations of daily physical activity and profile differences 24 
between less and more active patients with precapillary PH. A prospective, cross-25 
sectional study of 20 patients with precapillary PH who undertook a) a comprehensive 26 
clinical assessment, b) a preliminary treadmill test, c) 7-day monitoring of daily walking 27 
intensity with triaxial accelerometry and d) a personalized treadmill test corresponding to 28 
the individual patient mean daily walking intensity with real-time physiological 29 
measurements. Significant clinical correlations with individual patient mean walking 30 
intensity (1.71±0.27 m/s2) were observed for log N-terminal pro-brain natriuretic peptide 31 
(log-NTproBNP: r=-.75, p=<.001), age (r=-.70, p=.001), transfer factor for carbon 32 
monoxide %predicted (r=.51, p=0.022) and 6-minute walk distance (r=.50, p=.026). 33 
Significant physiological correlations were obtained for heart rate reserve (r=.68, 34 
p=.001), quadriceps tissue oxygenation index (Q-StO2: r=.58, p=.008), change in Q-StO2 35 
from rest (r=.60, p=.006) and ventilatory equivalent for oxygen uptake (r=-.56, p=.013). 36 
Stepwise multiple regression analyses retained log-NTproBNP (R2=0.55), heart rate 37 
reserve (R2=0.44) and Q-StO2 (R
2=0.13) accounting for a significant variance in 38 
individual walking intensity. Less active patients had greater physical activity-induced 39 
cardiopulmonary impairment, worse quadriceps oxygenation profile and compromised 40 
health-related quality of life compared to more active patients. These preliminary 41 
findings suggest a significant relation between right ventricular and peripheral muscle 42 
oxygenation status and reduced daily physical activity in precapillary PH. Further 43 
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research is warranted to unravel the physiological determinants, establish clinical 44 
predictors, and identify beneficial interventions. 45 
New & Noteworthy 46 
Daily physical activity holds promise to be meaningful, patient-related outcome 47 
measure in pulmonary hypertension. Herein, novel findings in a representative sample of 48 
patients with precapillary pulmonary hypertension link reduced daily walking activity, as 49 
measured by triaxial accelerometry with compromised right ventricular and pulmonary 50 
vascular status, peripheral muscle oxygenation and health-related quality of life. Thus, 51 
this study provides preliminary insight into the physiological mechanisms and clinical 52 
predictors of daily physical activity in precapillary pulmonary hypertension.  53 
Keywords: pulmonary arterial hypertension, daily physical activity, right ventricle, 54 
skeletal muscle oxygenation.55 
 4 
Introduction 56 
Precapillary pulmonary hypertension (PH) comprises primarily pulmonary arterial 57 
hypertension (PAH; group 1) and chronic thromboembolic pulmonary hypertension 58 
(CTEPH; group 4) and is characterised by progressive elevation of vascular resistance in 59 
the precapillary pulmonary vasculature and right heart failure (13).  Despite important 60 
advances in the understanding and targeted therapy to date, the morbidity and mortality in 61 
precapillary PH remain high: typically, patients suffer progressive dyspnoea, impaired 62 
exercise capacity and health-related quality of life (HRQoL), and premature death (1, 13, 63 
37).  64 
Physical activity is defined as the bodily movement produced by the contraction of 65 
skeletal muscle that increases energy expenditure above the basal level and can be 66 
described by dimensions of intensity, frequency, duration, mode and context (14). Daily 67 
physical activity is an important dimension of HRQoL in cardiopulmonary disease (10, 68 
43) and satisfies the core requirement of a meaningful patient-centered endpoint in 69 
clinical trials, defined to be a direct measure of how a patient “feels, functions or 70 
survives” where “function” refers to the ability to carry out normal daily activities (15). 71 
Accordingly, enhancement of daily physical activity is recommended in PH (13); 72 
however, research shows significantly reduced daily physical activity in patients with 73 
precapillary PH compared to healthy controls and poorer survival in more sedentary 74 
patients (21, 36, 39, 45).  75 
The causes of reduced daily physical activity in PH are not adequately explored.  Our 76 
perception on the underlying mechanisms remains intuitively focused on pulmonary 77 
vasculopathy and right ventricular dysfunction and limited to extrapolations from 78 
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standardized exercise testing (40), which may not correspond well to daily physical 79 
activity (28, 47). Importantly, the role of peripheral muscles has not been investigated. 80 
This is despite growing evidence on skeletal muscle abnormalities in PAH (31) and 81 
recent findings suggesting that estimates of skeletal muscle oxygenation may reflect the 82 
pathophysiology of PAH (32, 33). Importantly, the surrogate value of common clinical 83 
tools in precapillary PH in the prediction of daily physical activity is not well established. 84 
The purpose of this study was therefore to explore the physiological mechanisms and 85 
predictors of reduced physical activity in precapillary PH. To this aim, we investigated 86 
relations of patient daily walking intensity as measured by accelerometry with a) routine 87 
clinical measures and b) cardiopulmonary and peripheral muscle physiological responses 88 
during laboratory exercise corresponding to individual daily walking intensities. We also 89 
explored profile differences between less and more active patients. We hypothesized that 90 
along with pulmonary vasculature and right ventricular status, peripheral muscle function 91 
might be a pertinent factor to reduce daily physical activity in precapillary PH. 92 
Materials & Methods 93 
Study Sample  94 
Consecutive patients with stable PAH and technically non-operable (distal) CTEPH 95 
who attended the Scottish Pulmonary Vascular Unit between November 2014 and 96 
October 2015 were eligible. The diagnosis had been previously established by right heart 97 
catheterisation as recommended (13). Clinical stability was defined as a) no 98 
hospitalization for precapillary PH and b) no escalation in therapy for PH or diuretics 99 
within 3 months. Exclusion criteria were pulmonary endarterectomy or comorbidities 100 
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interfering with physical activity and treadmill testing. Approval from the West of 101 
Scotland Research Ethics Committee (14/WS/1075) and written consent were obtained. 102 
Initial evaluation 103 
Subjects had determination of WHO functional class, maximum voluntary ventilation 104 
(MVV=FEV1 x 35)
 (1) and transfer factor for carbon monoxide (TLCO) corrected for 105 
haemoglobin concentration. (19). They also completed the patient-reported Cambridge 106 
Pulmonary Hypertension Outcome Review (CAMPHOR) (25) and emPHasis-10 (48), 107 
two well-validated questionnaires for the assessment of HRQoL in PH. CAMPHOR is 108 
probably the most widely studied questionnaire in PH and has been shown to predict 109 
clinical deterioration in idiopathic PAH and CTEPH (24). However, neither CAMPHOR 110 
nor emPHasis-10 questionnaires have been validated against objective, accelerometry 111 
measures of daily physical activity to date. 112 
Finally, N-terminal pro-brain natriuretic peptide (NTproBNP) and 6-minute walk 113 
distance (6MWD) were retrieved from the medical record (median interval: 30 days for 114 
both). 115 
Preliminary treadmill test 116 
Subjects performed an incremental treadmill test (RAM 770M; RAM Medical and 117 
Industrial Instruments & Supplies, Padova, Italy) at an initial speed of 1.4 km/h that 118 
increased by 0.8 km/h every 3 minutes to the limit of tolerance as previously described 119 
(17, 18). The treadmill speed was determined by a communicating ergospirometry testing 120 
system (CASE ES, GE Healthcare, Freiburg, Germany). Minute-by-minute walking 121 
intensity was measured concurrently in units of acceleration (m/s2) using a triaxial 122 
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activity monitor (DynaPort MoveMonitor; McRoberts, Netherlands). In this manner, a 123 
range of intensities was obtained at various speeds and a graph of walking intensity 124 
against treadmill speed was plotted for each patient. This was used to calculate a 125 
treadmill speed corresponding to each patient’s mean daily walking intensity, as 126 
described below. 127 
Accelerometry 128 
Subjects were fitted with DynaPort accelerometers attached to an elastic strap and 129 
positioned over L2 vertebra (an approximation of body’s center of mass) to record their 130 
daily walking intensity continuously for 7 days, excluding sleep and water-based 131 
activities. Measurements were considered sufficient if technically acceptable signal was 132 
obtained daily for a minimum of 12 consecutive hours, during 5 consecutive days (18, 133 
34).  134 
The DynaPort is a validated accelerometer that provides reliable measures of physical 135 
activity including postures, steps and movement intensities even under sedentary 136 
conditions (5, 37, 46). The intensity with which a person carries out activities of daily 137 
living is a fundamental part of recommendations for health maintenance (14) and an 138 
important aspect of the overall physical activity (17, 18). 139 
Personalized treadmill test 140 
Within 2 weeks, patients underwent a final, three-stage treadmill protocol during 141 
which they sequentially: a) stood still on treadmill, b) warmed up at a speed of 1.4 km/h, 142 
and c) walked at a predetermined treadmill speed corresponding to their individual daily 143 
walking intensity (calculated by using the data from the preliminary test and monitoring 144 
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of daily walking intensity). The duration of each stage was 4 minutes in order to reach 145 
steady physiological state (18). Continuous physiological measurements were obtained 146 
throughout as described below. The resting and exercise value for each variable was the 147 
average value obtained during the last minute of the first and third stage, respectively. 148 
Metabolic profile 149 
Oxygen uptake (VO2), minute ventilation (VE) and ventilatory equivalent ratio for 150 
oxygen uptake (VE/VO2) and carbon dioxide (VE/VCO2) were recorded breath-by-breath 151 
(CASE ES, GE Healthcare, Freiburg, Germany). Oxyhaemoglobin saturation (SpO2) was 152 
recorded continuously by pulse oximetry (OxywatchTM MD300C63, Beijing Choice 153 
Electronic Tech. Co. Ltd, China). Electrocardiography was used to calculate heart rate 154 
(HR) reserve (HRR) defined as the difference between age-predicted maximal HR (220-155 
age) and peak HR (1). 156 
Central hemodynamics 157 
Estimates of stroke volume and cardiac output were measured using impedance 158 
cardiography technology (PhysioFlow®, Manatec Biomedical, France). PhysioFlow uses 159 
variations in the transthoracic impedance to a high-frequency (75 kHz), low-amperage 160 
(1.8 mA) alternating current across the thorax during cardiac ejection to calculate stroke 161 
volume (4) and it has been previously validated (42) and used in PAH (12). Application 162 
of six transthoracic electrodes, autocalibration, verification of signal quality and artifact 163 
detection were performed as instructed by the manufacturer and described elsewhere (4). 164 
Quadriceps oxygenation 165 
Quadriceps tissue oxygenation index (Q-StO2), as an expression of the local 166 
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microvascular oxygenation status, was measured using spatially resolved near infrared 167 
spectroscopy (NIRO-200NX®, Hamamatsu Photonics KK, Japan). Tissue oxygenation 168 
index is essentially the ratio of oxygenated to total tissue hemoglobin concentration 169 
expressed as [oxyhaemoglobin/(oxyhaemoglobin + deoxyhaemoglobin)] × 100 (%) and 170 
represents an index of the dynamic balance between local tissue oxygen delivery and 171 
utilisation in health and disease (3, 23). We have previously shown strong correlations 172 
between Q-StO2 and mixed venous oxygen saturation measured at pulmonary artery in 173 
PAH subjects, both at rest and exercise (32, 33). 174 
To measure Q-StO2, one transcutaneous probe (S-type) housed in a black rubber 175 
holder and fixed using a double-sided adhesive tape, was placed on the belly of each 176 
vastus lateralis muscle, 10-12 cm above the lateral epicondyle. The values shown for Q-177 
StO2 are the average from both legs. Estimated systemic oxygen delivery was calculated 178 
as the product of cardiac output and arterial oxygen content; the latter was calculated as 179 
the product of 1.34 × hemoglobin concentration × %SpO2. The systemic arteriovenous 180 
oxygen content difference (a-vO2 difference) was calculated by dividing oxygen uptake 181 
by cardiac output (Fick principle) whereas the systemic oxygen extraction ratio was 182 
calculated as the ratio of the a-vO2 difference to arterial oxygen content (18). 183 
Statistical analysis 184 
Data are reported as means ± SD or median with 95% confidence interval of median. 185 
NTproBNP was log-transformed due to positive skewing. Associations of mean daily 186 
walking intensity were examined using the Pearson’s correlation coefficient. Significant 187 
parameters were further tested using stepwise multiple regression analysis. Patients were 188 
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dichotomised using the median daily walking intensity for an unpaired group comparison 189 
using the Mann-Whitney U-test. Data were analyzed using the SPSS statistical package 190 
(v 20, SPSS Inc., Chicago, IL). The level of significance was set at p<.05. On the basis of 191 
data from a previous study (18), the critical sample size to achieve a power of 80% for 192 
detection of differences between patient groups with two-sided level of significance <.05 193 
was 16 patients (calculated using the Stata package; StataCorp LP, Texas, USA). 194 
Results 195 
Patient characteristics 196 
Patients characteristics are presented in Table 1. Twenty patients enrolled, completed 197 
the protocol without adverse effects and included in the analysis (Figure 1). Stroke 198 
volume profile of 3 (15%) patients had to be excluded due to invalid impedance 199 
cardiography signal. Sixteen patients had PAH (9, idiopathic PAH; 6, connective tissue 200 
disease associated-PAH; 1, PAH after correction of congenital heart disease) and 4 201 
patients had CTEPH. None of the patients had significant cardiac shunt detected at right 202 
heart catheterisation or follow-up echocardiograms. All patients were on PH-specific 203 
therapy: 10, monotherapy (7, phosphodiesterase-5 inhibitor (PDEi); 2, stimulator of 204 
soluble guanylate cyclase (sGC); 1, endothelin receptor antagonist (ERA)) and 10, 205 
combination therapy (6, PDE-i+ERA; 1, ERA+sGC; 3, PDEi+ERA+inhaled prostanoid). 206 
None of the patients was on heart rate-limiting medication. 207 
Total and daily time of accelerometry monitoring were 6.4±0.94 days and 864±94 208 
min, respectively. Mean and median daily walking intensity were 1.71±0.27 m/s2 and 209 
1.78 (1.55, 1.83) m/s2, respectively. Daily walking time was 61±26 min and daily steps 210 
4897±2209.  211 
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Correlations and predictors of daily walking intensity 212 
Significant clinical correlations with mean daily walking intensity were observed for 213 
log-NTproBNP (r=-.75, p=<.001), age (r=-.70, p=.001) and 6MWD (r=.50, p=.026) 214 
(Table 1; Figure 2). Significant physiological correlations with mean daily walking 215 
intensity were observed for HRR (r=.68, p=.001), Q-StO2, (r=.58, p=.008), change in Q-216 
StO2 from rest to mean daily walking intensity (r=.60, p=.006), VE/VO2 (r=-.56, p=.013) 217 
and TLCO %predicted (r=.51, p=0.022) (Table 2; Figure 2). There was no association 218 
between estimates of stroke volume at rest or exercise and mean daily walking intensity  219 
Stepwise multivariate regression analysis of significant clinical measures retained log-220 
NTproBNP (b=-.290±.068, β=-.554, p=.001) and age (b=-.008±.002, β=-.486, p=002) 221 
accounting for 55% and 20% of the variance in mean daily walking intensity, 222 
respectively. Repeated for the significant physiological measures, analysis retained HRR 223 
(b=.006±.002, β=.506, p=.015) and Q-StO2 at activity (b=.01±.005, β=.395, p=.049) 224 
accounting for 44% and 13% of the variance in mean daily walking intensity, 225 
respectively. 226 
Comparison between less and more active patients 227 
There was no significant difference in VO2 between less and more active patients. 228 
Less active patients had significantly increased age, log-NTproBNP, VE/MVV, VE/VO2, 229 
CAMPHOR and emPHasis-10 scores and decreased TLCO %predicted, HRR, Q-StO2 at 230 
mean daily walking intensity and Q-ΔStO2; they also showed 100-meter reduction in 231 
6MWD compared to more active patients (for all numerical values and P-values see 232 
Table 1 and 2).  233 
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 234 
Discussion 235 
This exploratory study in a representative cohort with precapillary PH, reports on 236 
significant associations of indices of right ventricular (log-NTproBNP, HRR) and 237 
pulmonary vascular (TLCO %predicted) status with mean daily walking intensity. In 238 
exercise conditions reproducing individual daily physical activity levels, measures of 239 
quadriceps oxygenation (Q-StO2 at activity, ΔQ-StO2) and ventilatory efficiency 240 
(VE/VO2) were also associated significantly with mean daily walking intensity. log-241 
NTproBNP, HRR and Q-StO2 at mean activity levels predicted a significant variance in 242 
mean daily walking intensity. Finally, the profile of less active patients comprised greater 243 
cardiorespiratory impairment, worse quadriceps oxygenation profile and compromised 244 
HRQoL compared to more active patients.   245 
Walking intensity is an important aspect that a patient with lung disease adopts in 246 
daily living For example, numerous studies (Watz et al ERJ 2014; 44(6): 1521-1537) 247 
have emphasized the finding that the intensity of movement adopted by COPD patients 248 
during walking is reduced by an average 0f 17 to 33% compared to healthy age-matched 249 
individuals. Daily walking intensity in the present cohort (1.7 m/s2) favorably compares 250 
with that adopted by older patients with moderate/severe COPD (spirometric classes 251 
II/III), typically corresponding to 1.8 m/s2 (18, 34). Overall, the present population 252 
adopted a sedentary (most commonly) or low-active lifestyle defined as daily steps of 253 
<5000 and between 5000-7500, respectively (43). This adds to previous evidence (21, 36, 254 
39, 45) on reduced measures of daily physical activity in precapillary PH.  255 
The hemodynamic profile in precapillary PH depends mostly on the right ventricular 256 
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performance (16). NT-proBNP, a nonspecific marker of myocardial dysfunction, is 257 
considered an indicator of the right ventricular status and a prognostic marker at 258 
diagnosis and during follow-up in precapillary PH (13). Out of 35 variables, NT-proBNP 259 
was also the strongest predictor of peak VO2 and a significant predictor of 6MWD in 260 
patients with chronic heart failure (11). In line, we observed a strong negative correlation 261 
between log-NTproBNP and mean daily walking intensity whereas log-NTproBNP 262 
predicted more than half of the variance in mean daily walking intensity and it was 263 
significantly higher in less active patients. 264 
Heart rate profiles in precapillary PH are though to reflect the burden of the right 265 
ventricle (16).  In the setting of right ventricular failure and ensuing fixed/reduced stroke 266 
volume, patients with precapillary PH become dependent on compensatory increase in 267 
HR responses to maintain or increase cardiac output and preserve tissue oxygenation (16). 268 
Hence, the HR-VO2 relationship in precapillary PH is left-shifted with submaximal HR 269 
values trending higher than normal (1). Accordingly, chronotropic response (peak 270 
walking HR minus resting HR) and resting HR in PAH, have been independently 271 
associated with 6MWD (35) and prognosis (16), respectively. Here, we extend these 272 
findings by showing a strong relation between HRR and mean daily walking intensity 273 
and significantly reduced HRR in less active 274 
 patients compared to more active patients. HRR also predicted almost half of the 275 
variance in individual mean daily walking intensity. 276 
The higher HR accounted for the higher cardiac output in less active patients in the 277 
present study; estimates of stroke volume did not differ between less and more active 278 
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patients and it was dissociated with daily walking activity. Cardiac output as such also 279 
did not correlate with daily walking intensity in the present cohort. Previous studies using 280 
right heart catheterisation data also failed to show correlation between cardiac 281 
output/index and daily physical activity levels in precapillary PH (21, 36). In contrast, 282 
TLCO %predicted, reflecting pulmonary capillary volume, was also negatively 283 
associated with mean daily walking intensity and 40% lower in less active patients. 284 
Collectively, our findings on NT-proBNP and HRR profiles and, TLCO %predicted 285 
speak for a significant relation between the right ventricular and pulmonary capillary 286 
volume status and daily physical activity in precapillary PH.  287 
The ventilatory response becomes exaggerated in precapillary PH due to 288 
chemo/ergo/baro- receptor sensitivity, dead space ventilation and hypoxemic drive. 289 
Premature lactic acidosis at the peripheral muscles due to hypoxemia will also increase 290 
the ventilatory drive on activity. Physiologically, the ventilatory response to the 291 
metabolic requirement is reflected in the VE/VO2 relationship
 (1). Accordingly, we 292 
observed a negative correlation between VE/VO2 and mean daily walking intensity 293 
whereas VE/VO2 and VE/MVV were significantly higher among less active patients (by 294 
almost 20% and 40%, respectively). VE/VCO2, ratio, another important index of 295 
ventilatory efficiency and of prognostic significance in precapillary PH, also differed 296 
between the 2 groups (58 vs. 44); however, it did not reached statistical significance, 297 
possibly, due to submaximal testing and small sample. Such an exaggerated ventilatory 298 
response is highly relevant to physical activity as it may promote dyspnoea and cessation 299 
of exercise.  300 
Patients with PAH exhibit significant morphological and functional changes of 301 
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quadriceps muscle including alteration in the muscle fibre type, muscle atrophy, reduced 302 
capillarity and oxidative capacity, and endothelial dysfunction (31). These abnormalities 303 
may impair the local tissue oxygen delivery and utilization capacity, muscle strength and 304 
exercise capacity (20). Importantly, muscle characteristics were unrelated to the 305 
hemodynamic severity (20) and targeted exercise training reversed abnormalities and 306 
improved exercise capacity (6, 26), which suggest that peripheral muscle abnormalities 307 
may be implicated independently in the exercise pathophysiology of PAH. Here, Q-StO2
 308 
at activity correlated with mean daily walking intensity, predicted a clinically significant 309 
amount of the variance in daily walking intensity, and was significantly lower in less 310 
active patients. Importantly, ΔQ-StO2 responses opposed between patient groups: less 311 
active patients drop Q-StO2 whereas more active patients benefited from increased Q-312 
StO2 at individual mean daily walking intensity. 313 
Factors determining local muscle oxygenation are modulated by the rate of oxygen 314 
delivery and oxygen extraction (8). Whereas arterial oxygen content and systemic oxygen 315 
delivery did not differ between the present patient groups, less active patients had 316 
significantly reduced a-vO2 difference and ~ 10% reduction in oxygen extraction ratio 317 
compared to more active patients. Collectively, our novel findings on estimates of muscle 318 
oxygenation suggest a strong relation between capacity to enhance local muscle 319 
oxygenation and better preserved daily physical activity and they provide support to the 320 
peripheral muscle hypothesis (29). They also add to previous evidence showing: a) 321 
impaired oxygen extraction rate during maximal exercise in PAH patients compared to 322 
patients with pulmonary venous hypertension (41); b) lower thenar muscle resting StO2 in 323 
PAH compared to CHF and healthy subjects (9); c) greater quadriceps oxygen delivery-324 
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to-utilization inequalities (Δ[Mb-HHb]; change in deoxygenated myoglobin from rest to 325 
exercise) in PAH compared to healthy subjects, which accounted for a slower rate of 326 
adaptation of aerobic metabolism at exercise (2); and d) reduced quadriceps oxygenation 327 
(lower Q-ΔStO2, higher Δ[Mb-HHb]) in PAH compared to normal subjects even during 328 
submaximal exercise (22); Δ[Mb-HHb] was also related to reduced quadriceps capillarity 329 
and strength, and lower VO2
 (22). 330 
Certainly, our study design does not allow for proof of causality and further research is 331 
required before a primary impairment of peripheral muscle oxygenation is considered a 332 
true limiting factor rather than a mere consequence of deconditioning, or reflection of 333 
hypoxemia. Nonetheless, we found no association between Q-StO2 and SpO2 or arterial 334 
oxygen content at rest/exercise (p>0.5 for all). Furthermore, Q-ΔStO2 and Δ[Mb-HHb] in 335 
PAH subjects have been previously shown to remain unchanged with oxygen 336 
supplementation (22).  337 
A unified explanation may lie within the seemingly paradoxical absence of difference 338 
in VO2 between less and more active patients. It is possible that the metabolic 339 
requirements of the increased workload (reduced HRR) of the stressed heart (increased 340 
log-NTproBNP) and increased/inefficient ventilation (increased VE/MVV, VE/VO2) in 341 
less active patients had matched the oxygen requirements of increased daily walking 342 
intensity in more active patients. Teleologically, it may that both patient groups had 343 
adjusted their activity to a certain threshold of oxygen/energy cost that allowed for 344 
acceptable exertional symptoms such as muscle fatigue and breathlessness (as suggested 345 
by responses in ventilation and estimates of quadriceps oxygenation). Ultimately, less 346 
active patients showed convincingly compromised HQoL (worse CAMPHOR and 347 
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emPHasis-10 scores). 348 
The current study is limited by its cross-sectional design, small sample and small 349 
number of patients with advanced disease willing to undergo such a complex study 350 
protocol. Stroke volume profile of 3 (15%) patients had to be excluded due to invalid 351 
impedance cardiography signal but this limitation is inherent to impedance cardiography 352 
and this figure is similar to previously published experience in precapillary PH (12). 353 
Furthermore, the absence of direct measurement of peripheral muscle strength does not 354 
allow for further exploration of the role of the peripheral muscle. Impedance 355 
cardiography and Arterial oxygen content was estimated from using continuous SpO2 356 
readings at the expense of possible reduced accuracy in the hypoxaemic patients 357 
compared to invasive arterial blood sampling. For patient comfort, measurements of 358 
6MWD and NT-proBNP were retrospective in nature. However, we believe that in the 359 
context of clinical stability (a prerequisite for patient inclusion in the study), an interval 360 
of 30 days is an acceptable collection period for both measures. Finally, this study did not 361 
investigate the possible impact of specific diseases and drug therapy on muscle function 362 
or the effect of unmeasured variables such as environmental, social and personal factors 363 
to daily physical activity. These factors might have accounted for the unexplained 364 
variance in daily walking intensity and the moderate correlation of 6MWD with daily 365 
walking intensity. Of note, neither CAMPHOR or emPHasis-10 scores correlated with 366 
daily walking activity. Taken together with previously shown weak-to-moderate 367 
correlations of accelerometry data with 6MWD and patient-reported questionnaire scores 368 
(39), these findings question the surrogate value of routine clinical tools in the prediction 369 
of daily physical activity in precapillary PH. 370 
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 372 
Conclusions 373 
Daily physical activity holds promise to be meaningful, patient-related outcome 374 
measure in PH. Our preliminary findings suggest a significant relation between right 375 
ventricular and pulmonary vascular status, peripheral muscle oxygenation and HQoL 376 
with reduced daily physical activity in precapillary PH. However, further research is 377 
warranted to unravel the physiological determinants and establish the clinical predictors 378 
of this phenomenon. The role of muscle function in the natural history of precapillary PH 379 
merits particular focus as it offers a potential target for effective interventions.380 
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Figure Captions 389 
Figure 1: Study flow chart. BMI: body mass index; WHO FC: World Health 390 
Organization functional class; TLCO: transfer factor for carbon monoxide; 6MWD: 6-391 
minute walk distance; log-NTproBNP: log-transformed N-terminal pro-brain natriuretic 392 
peptide. VO2: oxygen uptake; VE: minute ventilation; MVV: maximum voluntary 393 
ventilation; VE/VO2: ventilatory equivalent ratio for oxygen; VE/VO2: ventilatory 394 
equivalent ratio for carbon dioxide; SpO2: oxyhaemoglobin saturation; HRR: heart rate 395 
reserve; SV: stroke volume; CO: cardiac output; Q-StO2: quadriceps tissue oxygenation 396 
index; Q-ΔStO2: change in Q-StO2 from rest to exercise. * Retrospective data (median 397 
interval: 30 days); § Resting and exercise value was the average value obtained during the 398 
last minute of the first and third stage, respectively; # SV/CO profile of 3 patients was 399 
excluded due to invalid impedance cardiography signal. 400 
Figure 2: Correlations (Pearson’s r) between daily walking intensity recorded by 401 
triaxial accelerometer and log N-terminal pro-brain natriuretic peptide (log-NTproBNP) 402 
(A); age (B); heart rate reserve (HRR) (C); ventilatory equivalent ratio for oxygen uptake 403 
(VE/VO2) (D); quadriceps tissue oxygenation index (Q-StO2) at activity (E); and change 404 
in Q-StO2 from rest to activity (Q-ΔStO2) (F) in 20 patients with precapillary pulmonary 405 
hypertension.  406 
 407 
 408 
Daily physical activity in precapillary PH. 
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Table 1: Clinical characteristics and comparison between less and more active patients1 409 
  Daily walking intensity, m/s2 P-value 
 
Variable All (n=20) < 1.78 (n=10) ≥ 1.78 (n=10)  
Walking Intensity, m/s2 1.71 ± 0.27 1.54 (1.29-1.75) 1.86 (1.79-2.03) <.001* 
Treadmill speed, km/hr 2.27 ± .84 1.90 (1.00-2.90) 2.95 (1.80-3.20) .037 
Sex, m/f 8/12 4/6 4/6 N/A 
Age, yr 54.1 ± 15.9 66.0 (44.0-73.0) 48.5 (24.0-56.0) .045* 
BMI, kg/m2 29.9 ± 5.7 28.1 (18.8-31.6) 25.5 (21.3-29.7) .705 
Diagnosis     
Idiopathic PAH 9 4 5 N/A 
CTD-PAH 6 4 2 N/A 
CHD-PAH 1 0 1 N/A 
CTEPH 4 2 2 N/A 
WHO FC, I/II/III 4/12/4 1/5/4 3/7/0 N/A 
mean PAP, mm Hg 45.1± 13.3 46.0 (32.0-57.0) 40.0 (28.0-65.0) .713 
                                                     
1 Values are expressed as means ± SD or median and 95% confidence interval of median. BMI: 
body mass index; PAH: pulmonary arterial hypertension; CTD-PAH: connective tissue disease 
associated PAH; CHD-PAH: PAH after correction of congenital heart disease; WHO FC: World 
Health Organization functional class; PAP, CO and PVR: historical pulmonary arterial pressure, 
cardiac output and pulmonary vascular resistance, respectively, measured at diagnostic right 
heart catheterization, prior to the initiation of PH-specific therapy; 6MWD: 6-minute walk 
distance; log-NTproBNP: log-transformed N-terminal pro-brain natriuretic peptide; TLCO: 
transfer factor for carbon monoxide. *Significant statistical difference between patient groups. 
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CO, L/min 3.8 ± 1.0 3.6 (2.6-4.3) 4.3 (3.3-5.0) .102 
PVR, Wood units 11.1 ± 5.7 12.3 (6.0-13.5) 8.7 (4.8-15.2) .369 
6MWD, m 418 ± 106 361 (298-513) 469 (347-570) .076 
CAMPHOR 23.2 ± 16.8 36.5 (8.0-46.0) 11.5 (0-36.0) .041* 
emPHasis-10 21.9 ± 14.1 31.0 (12.0-38.0) 13.5 (0-32.0) .089 
log-NTproBNP, pg/mL 2.53 ± 0.53 2.99 (2.75-3.29) 2.10 (1.79-2.42) <.001* 
FEV1, %pred. 89.9 ± 19.1 93.0 (80.0-115.5) 91.0 (65.8-98.5) 0.26 
FVC, %pred. 112.4 ± 23.2 115.5 (100.3-141.5) 108.0 (90.0-122.3) 0.34 
FEV1/FVC 66.5 ± 8.5 69.0 (60.3-72.0) 66.5 (63.3-71.0) 0.62 
Daily physical activity in precapillary PH. 
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Table 2: Physiological characteristics and comparison between less and more active patients1. 410 
  Daily walking intensity, m/s2 P-value 
Variable All (n=20) < 1.78 (n=10) ≥ 1.78 (n=10)  
SpO2 activity, % 89.9 ± 7.1 86.0 (81.0-95.0) 95.0 (88.0-96.0) .1 
HRR, beats/min 61.8 ± 26.2 51.0 (9.0-57.0) 78.5 (67.0-91.0) <.001* 
SV rest/activity, ml/beat 66.5± 21.5/ 
80.9 ± 21.6 
59.2 (25.0-116.9)/ 
74.1 (42.9-137.0) 
63.6 (58.3-79.2)/ 
78.9 (72.0-91.2) 
.664/ 
.745 
CO rest/activity, l/min 5.4 ± 1.2 
8.9 ± 2.6 
5.2 (3.3-7.1) 
10.0 (6.8-16.1) 
4.8 (4.2-6.7) 
7.5 (6.8-9.3) 
.495/ 
.045* 
Q-StO2 rest/activity, % 64.1 ± 7.4/ 
65.4 ± 10.6 
63.7 (54.6-68.6)/ 
60.5 (43.4-74.5) 
65.7 (57.9-74.4)/ 
71.4 (62.0-76.4) 
.496/ 
.028* 
Q-ΔStO2, % 1.3 ± 6.6 -2.3 (-6.0-1.8) 5.1 (3.2-7.8) .003* 
VE/MVV, l/min 40.9 ± 14.3 48.9 (32.2-60.0) 30.5 (25.9-39.6) .007* 
VE/VO2 51.1 ± 18.8 55.8 (39.8-81.1) 40.6 (34.3-58.2) .041* 
VO2, ml·kg
-1·min-1 9.5 ± 1.4 9.4 (7.5-11.0) 9.7 (7.9-10.5) .806 
VE/VCO2 52.1 ± 13.6 57.7 (38.4-77.0) 44.0 (40.0-56.7) .142 
Arterial oxygen content, 18.1 ± 1.42 17.3 (16.3-19.1) 19.1 (17.7-19.3) .1 
                                                     
1 Values are expressed as means ± SD or median and 95% confidence interval of median. SpO2: 
oxyhaemoglobin saturation; HRR: heart rate reserve; SV: stroke volume; CO: cardiac output; Q-
StO2: quadriceps tissue oxygenation index; Q-ΔStO2: change in Q-StO2 from rest to exercise; VE: 
minute ventilation; MVV: maximum voluntary ventilation; VE/VO2: ventilatory equivalent ratio 
for oxygen; VE/VO2: ventilatory equivalent ratio for carbon dioxide; VO2: oxygen uptake; a-vO2 
difference: arterio-venous oxygen content difference. *Significant statistical difference between 
patient groups. 
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ml/dl 
Systemic oxygen 
delivery, l/min 
1.4 ± .5 1.6 (1.1-2.6) 1.4 (1.2-1.6) .556 
Systemic a-vO2  
difference difference, 
mlO2/100 ml 
7.7 ± 1.6 5.9 (5.1-8.3)  8.6 (6.7-9.8) .017* 
Systemic oxygen 
extraction, % 
42 ± 11 35 (28-51) 44 (34-52) .239 
Daily physical activity in precapillary PH. 
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